Evaluation of [¹⁸F]MODAG-009 PET Imaging in Synucleinopathies
NCT07640555
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
This is a single-center, open-label clinical study designed to evaluate the imaging characteristics and safety of [¹⁸F]MODAG-009 in participants with Parkinson's disease (PD), Multiple system atrophy (MSA), and Healthy controls (HC). Approximately 13 participants will be enrolled in this study. Each participant will receive a single intravenous injection of [¹⁸F]MODAG-009, followed by PET imaging using the investigational United Imaging NeuroEXPLORER (NX) camera.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Multiple System Atrophy (MSA)
- Healthy Adult
- Parkinson Disease
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Early Phase 1
- Ages
- 50 to 80 years
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- MODAG GmbH
- Last updated on ClinicalTrials.gov
- June 10, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Connecticut · 1
- Institute for Neurodegenerative Disorders and XingImaging, LLC · New Haven, CT
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.